No Data
No Data
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and tr
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of
Revelation Biosciences stock slides 47% on pricing $5M securities offering
Revelation Biosciences (NASDAQ:REVB) shares dropped 47% pre-market on Tuesday after the life sciences company priced its $5M securities offering. The offering consists of 8.33M shares of common stock
No Data